Skip to main content Skip to search Skip to main navigation

PDE Report | Sample Document

2 reviews

Average rating of 5 out of 5 stars


100%

0%

0%

0%

0%


Leave a review!

Share your experiences with other customers.

Review with rating of 5 out of 5 stars

Great information

Great information

Mohammed Abdalla Zayed

4 Jul 2022

Review with rating of 5 out of 5 stars

risk assessment

risk assessment

Wei Shao

28 Oct 2020

Product Information

Why do you need a PDE report?

As of June 1st, 2016, health-based exposure limits must be determined for all APIs of human and veterinary medicinal products produced in multi-purpose facilities.

Our service includes 

Issuing of the PDE report

  • According to EMA guideline in English
  • Issued on your company name according to EMA guideline requirements
  • Issued by European toxicological experts

This is what we need from you to prepare a quote:

  • Company name and address
  • Name of the API
  • Dosage form
  • Route of application of the API or of the potential next product produced in the same facility (for cleaning validation)
Request a quote

Do you Have any Questions?

Cynthia Schulz, Vertrieb und Key Account für Toxkologische Gutachten beim GMP-Verlag

Talk to our customer advisors

Do you have any questions about our products and services? We are here to help.

Customer Reviews

2 reviews

Average rating of 5 out of 5 stars


100%

0%

0%

0%

0%


Leave a review!

Share your experiences with other customers.

Review with rating of 5 out of 5 stars

Great information

Great information

Mohammed Abdalla Zayed

4 Jul 2022

Review with rating of 5 out of 5 stars

risk assessment

risk assessment

Wei Shao

28 Oct 2020

You may also be interested in the following products

Skip product gallery

h

OEL Categorisation | Sample Document

OEL Categorisation | Sample Document

Why do you need OEL categorisations? For every API, an upper limit on the acceptable concentration in workplace air has to be determined (OEL). For this determination, toxicological and pharmacological properties of the API are analysed and related to preventive measures.Our service includes extensive bibliographic researchOEL determination according to internationally accepted guidelines Categorisation with regard to the specific working conditions according to national requirements or SafeBridge® banding scheme This is what we need from you to prepare a quote Company name and address Name of the API Request a quote

delivery time appr. 2-5 workdays after receipt of payment
€0.00 net excl. VAT
Elemental Impurities Risk Assessment | Sample Document

Elemental Impurities Risk Assessment | Sample Document

Why do you need an elemental impurities risk assessment? As of June 2016, all new medicinal products have to be evaluated based on the ICH guideline Q3D on elemental impurities. As of December 2017, this guideline came into effect for already authorised medicinal products as well. Therefore, every authorised medicinal product has to be evaluated. How to obtain an elemental impurities risk assessment? The proven and successful collaboration between Dalia and GMP-Verlag Peither AG provides you with an economically priced alternative to conventional elemental impurities risk assessments. Following verification of the critical key data, we will be pleased to send you a binding, fixed price quote. Request a quote Our service includes Issuing of the elemental impurities risk assessment According to ICH Q3D guideline in English Issued for the specific medicinal product according to ICH Q3D guideline Issued by European toxicological experts This is what we need from you to prepare a binding, fixed price quote Company name and address Name of the medicinal product Request a quote

delivery time appr. 2-5 workdays after receipt of payment
€0.00 net excl. VAT
GMP:KnowHow Pharma Logistics (GDP) | Free Demo Access

GMP:KnowHow Pharma Logistics (GDP) | Free Demo Access

Your perfect tool for GDP-compliant storage and transportation The demo access is free and absolutely non-binding. It ends automatically after 7 days. How the GMP:KnowHow Pharma Logistics (GDP) supports you: Practical Knowledge Here, the respective GDP chapter is summarized and interpreted in simple terms. In particular, the practical implementation at a logistics service provider is considered in the interpretation. You also receive many editable sample documents. By the way – you can always ask our experts: Ask your specific questions directly form the online portal. Receive personal answers. Regulations All relevant GDP regulations are covered and are always up-to-date. You will find all relevant passages from the various pieces of legislation that have been assigned to the respective GDP chapter. This gives you a direct overview of the underlying regulatory requirements for each topic.

delivery immediately after receipt of payment
€0.00 net excl. VAT
GMP Compliance Adviser | Free Demo Access

GMP Compliance Adviser | Free Demo Access

You will receive your login credentials via email. Throughout the week, you will receive further information about GMP Compliance Adviser directly in your inbox. Customer support is available to assist you at any time. You can also direct questions about the content to the editorial team and receive personalized responses. You do not need to cancel your demo access. The free access will end automatically. Advantages at a glance

delivery time appr. 2-5 workdays after receipt of payment
€0.00 net excl. VAT

Recommended Articles

How is First Air Verified and Monitored During Aseptic Process Qualification?

How is First Air Verified and Monitored During Aseptic Process Qualification?

Here's the answer:
Read more
Outsourced Activities in the GDP Environment Part I: Supplier Management

Outsourced Activities in the GDP Environment Part I: Supplier Management

Supplier management is the systematic management of a company´s relationship with its suppliers. It encompasses supplier qualification and customer audits as described in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
FDA: Draft Guidance on Assessing Container Closure Systems for Drugs and Biologics

FDA: Draft Guidance on Assessing Container Closure Systems for Drugs and Biologics

On 14 August 2026, the US Food and Drug Administration (FDA) announced the publication of a new draft guidance document entitled ‘Container Closure Systems for Human Drugs and Biological Products’.

Read more
FDA: New FDA Commissioner Dr. Heidi Overton

FDA: New FDA Commissioner Dr. Heidi Overton

President Donald Trump has named White House aide Heidi Overton to lead the US Food and Drug Administration (FDA). Overton will fill the position previously held by Marty Makary, who left the agency in May. This announcement was made on Trump's Truth Social account on 19 August. Her nomination is subject to confirmation by the Senate.

Read more
IPEC: Stability Guide for Excipients has been Updated

IPEC: Stability Guide for Excipients has been Updated

The IPEC Stability Guide for Pharmaceutical Excipients has been updated and is now available as version 3 (2026), as announced on the IPEC (International Pharmaceutical Excipients Council) website.

Read more
EU: “Forever Chemicals” in a Conflict of Interests

EU: “Forever Chemicals” in a Conflict of Interests

On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.

Read more
Handover of Computerised Systems to the Operating Department

Handover of Computerised Systems to the Operating Department

The GMP-compliant handover of computerised systems to operations is a critical step in the Computer System Validation (CSV) lifecycle. Beyond go-live and hypercare, clearly defined responsibilities, comprehensive documentation and well-trained personnel are essential to maintaining a validated state throughout routine operation.
Read more
How is the Effectiveness of CAPAs Verified?

How is the Effectiveness of CAPAs Verified?

Here's the answer:
Read more
APIC: Publishes Updated “How to Do” Document for GDP for Active Pharmaceutical Ingredients

APIC: Publishes Updated “How to Do” Document for GDP for Active Pharmaceutical Ingredients

The Active Pharmaceutical Ingredients Committee (APIC) has published Version 3 of the document “GDP for APIs: How to Do” (June 2026) on its website. The document provides practical guidance on implementing Good Distribution Practice for active pharmaceutical ingredients.

Read more
TGA: Seeks Feedback on Planned Adoption of 11 International Scientific Guidelines

TGA: Seeks Feedback on Planned Adoption of 11 International Scientific Guidelines

Australia's regulatory authority, the TGA (Therapeutic Goods Administration), pursues a strategy of aligning its regulatory approaches as closely as possible with comparable international standards. These include the regulatory requirements of the EU, the FDA and the ICH. In this context, around 370 international scientific guidelines have already been adopted.

Read more
EU: Strengthened Cooperation with WHO on Pandemic Preparedness

EU: Strengthened Cooperation with WHO on Pandemic Preparedness

“Today public health faces a new kind of challenge: speed. Diseases move faster and are more unpredictable than ever, racing across borders and continents.”, said Hadja Lahbib, Commissioner for Equality, Preparedness and Crisis Management, upon signing an EU4Health contribution agreement worth over 4 million euros with the World Health Organisation’s (WHO) Hub for Pandemic and Epidemic Intelligence in Berlin on 24 July 2026.

Read more
PIC/S: Revised Recommendations on Qualification and Validation

PIC/S: Revised Recommendations on Qualification and Validation

PIC/S has published a fundamentally revised version of its “Recommendations on Qualification and Validation” (PI 006-4). The new document was issued on 30 July 2026, will enter into force on 1 October 2026, and replaces the 2007 edition. The revised document has been expanded from 26 to 49 pages.
Read more
Previous
Next